| Abstrakt: |
Competing Interests: Disclosure JT reports personal fees from AstraZeneca K.K., Boehringer-Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., MSD K.K., and Taiho Pharmaceutical Co. Ltd., outside the submitted work. KN reports grants and personal fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., MSD K.K., Nippon Boehringer, Takeda Pharmaceutical Co., Ltd.; grants from Daiichi Sankyo Co., Ltd, Nippon Boehringer, Pfizer Japan Inc., EPS International Co., Ltd, EPS Corporation, Kissei Pharmaceutical Co., Ltd., PAREXEL International Corp., IQVIA Services JAPAN K.K., SymBio Pharmaceuticals Limited., Syneos Health, Taiho Pharmaceutical Co., Ltd., Eisai Co., Ltd., PRA HEALTHSCIENCES, Mochida Pharmaceutical Co., Ltd., Covance Japan Inc., Japan Clinical Research Operations, GlaxoSmithKline K.K., MSD K.K., Sanofi K.K., PPD-SNBL K.K., SymBio Pharmaceuticals Limited, Sysmex Corporation, Medical Research Support; personal fees and other from Eli Lilly Japan K.K., Ingelheim Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc.; personal fees from Care Net, Inc, 3H Clinical Trial Inc., Kyowa Kirin Co., Ltd, Nippon Kayaku Co., Ltd., Medical Review Co., Ltd., Medical Mobile Communications Co., Ltd., Nikkei Business Publications, Inc., Amgen Inc., YODOSHA Co., Ltd., Yomiuri Telecasting Corporation, 3H Clinical Trial Inc., outside the submitted work. HH reports grants from AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., and Ono Pharmaceutical Co. Ltd.; personal fees from AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., KYORIN Pharmaceutical Co. Ltd., MSD K.K., Novartis pharmaceuticals K.K., Ono Pharmaceutical Co. Ltd., Pfizer Japan Inc., Shanghai Haihe Biopharm, and Taiho Pharmaceutical Co. Ltd outside the submitted work. |
